



R21/Matrix-M Malaria Vaccine

[Source: IE](#)

Serum Institute of India (SII), the world's largest vaccine manufacturer (by number of doses produced and sold globally), has shipped the first set of [R21/Matrix-M malaria vaccines](#) to countries in Africa.

- This vaccine has been developed by the **University of Oxford** and the **Serum Institute of India**.
 - It has been recommended for use by the [World Health Organization \(WHO\)](#) after meeting required safety, quality and effectiveness standards.
 - The first malaria vaccine, [RTS,S/AS01](#) was recommended by WHO to prevent malaria in children in October 2021.
- **Malaria** is a life-threatening disease caused by the [plasmodium parasite](#), which is transmitted to humans through the bites of infected female Anopheles mosquitoes.
 - As per **World Malaria report 2023**, there were 249 million cases of malaria in 2022 compared to 247 million cases in 2021.
 - In 2022, the **African Region** bore the heaviest malaria burden, with 94% of cases and **95% of deaths globally**.
- **India accounted for 1.4% of total malaria cases in the world** and saw a 30% decline in malaria cases and 34% decline in deaths in 2022 as compared to the 2021.

Read more: [R21/Matrix-M Malaria Vaccine](#)

PDF Refernece URL: <https://www.drishtias.com/printpdf/r21-matrix-m-malaria-vaccine-1>